OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press12810.17650/1818-8346-2014-9-4-560-578HEMATOPOIETIC STEM CELL TRANSPLANTATIONТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК У ПАЦИЕНТОВ С ГЕМОБЛАСТОЗАМИUse of plerixafor for hematopoietic stem cells mobilization in allograft donorsПрименение плериксафора для мобилизации гемопоэтических стволовых клеток у доноров аллогенного трансплантатаBalashovD. N.БалашовД. Н.
Russian Federation
bala8@yandex.ruKurnikovaE. E.КурниковаЕ. Е.
Russian Federation
MaschanM. A.МасчанМ. А.
Russian Federation
SkvortsovYu. V.СкворцоваЮ. В.
Russian Federation
ShelikhovaL. N.ШелиховаЛ. Н.
Russian Federation
TrakhtmanP. E.ТрахтманП. Е.
Russian Federation
BoyakovaE. V.БояковаЕ. В.
Russian Federation
SkorobogatovaE. V.СкоробогатоваЕ. В.
Russian Federation
NovichkovaG. A.НовичковаГ. А.
Russian Federation
MaschanA. A.МасчанА. А.
Russian Federation
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, MoscowФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России, Москва1, Samory Mashela st., Moscow, Russia, 117198117198, Россия, Москва, ул. Саморы Машела, 1Russian Children’s Clinical Hospital, Ministry of Health of Russia, MoscowФГБУ «Российская детская клиническая больница» Минздрава России, Москва117, Leninskiy ave., Moscow, Russia, 117513117513, Россия, Москва, Ленинский просп., 1173012201494242730012015300120152014https://oncohematology.abvpress.ru/ongm/article/view/128

Unsuccessful mobilization of hematopoietic stem cells (HSCs) before apheresis in allograft donor is a factor adversely affecting the characteristics of the obtained cell product and, as a consequence, the therapy outcome. This study investigates the efficacy and safety of plerixafor as an additional alternative drug for HSCs mobilization after nsuccessful mobilization using G-CSF. Mobilization of HSC in all cases was performed using a preparation of G-CSF during 5 days. The ineffectiveness of this in 17 donors was revealed on the fourth day from the beginning of the mobilization, and therefore plerixafor was administered to all donors in this cohort 11–12 hours before cytapheresis. Use of plerixafor allowed obtaining a transplant with good cellular characteristics in all cases. Plerixafor safety profile comparable with GCSF has also been demonstrated. Based on the results of this study it was concluded about efficacy and feasibility of plerixafor as “rescue” therapy after unsuccessful mobilizationwith G-CSF.

plerixaforG-CSFallogeneic transplantationhematopoietic stem cellsmobilizationalternative technologydonorsapheresisefficacysafetyside effectsплериксафорГ-КСФаллогенная трансплантациягемопоэтические стволовые клеткимобилизацияальтернативная технологиядонорцитаферезэффективностьбезопасностьпобочные эффекты1. Hopman R.K., DiPersio J.F. Advances in stem cell mobilization. Blood Reviews 2014;28:31–40.Hopman R.K., DiPersio J.F. Advances in stem cell mobilization. Blood Reviews 2014;28:31–40.2. Kuittinen T., Nousiainen T., Halonen P. et al. Prediction of mobilisation failure in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 2004;33(9):907–12.Kuittinen T., Nousiainen T., Halonen P. et al. Prediction of mobilisation failure in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 2004;33(9):907–12.3. Ferraro F., Lymperi S., Méndez-Ferrer S. et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011;3(104):article 104ra101.Ferraro F., Lymperi S., Méndez-Ferrer S. et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011;3(104):article 104ra101.4. Devine S.M., Flomenberg N., Vesole D.H. et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 2004;22:1095–102.Devine S.M., Flomenberg N., Vesole D.H. et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 2004;22:1095–102.5. Flomenberg N., Devine S.M., Dipersio J.F. et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867–74.Flomenberg N., Devine S.M., Dipersio J.F. et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867–74.6. Fowler C.J., Dunn A., Hayes-Lattin B. et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009;43:909–17.Fowler C.J., Dunn A., Hayes-Lattin B. et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009;43:909–17.7. Sinha S., Gastineau D., Micallef I. et al. Predicting PBSC harvest failure using circulating CD34 levels: developing targetbased cutoff points for early intervention. Bone Marrow Transplant 2011;46(7):943–9.Sinha S., Gastineau D., Micallef I. et al. Predicting PBSC harvest failure using circulating CD34 levels: developing targetbased cutoff points for early intervention. Bone Marrow Transplant 2011;46(7):943–9.8. Wolschke C., von Pein U., Klyuchnikov E. et al. Plerixafor (AMD3100) in combination with filgrastim for mobilization of peripheral blood stem cells by HLA-identical sibling donor in setting of allogeneic stem cell transplantation. EBMT Meeting 2013, London. P. 702.Wolschke C., von Pein U., Klyuchnikov E. et al. Plerixafor (AMD3100) in combination with filgrastim for mobilization of peripheral blood stem cells by HLA-identical sibling donor in setting of allogeneic stem cell transplantation. EBMT Meeting 2013, London. P. 702.9. Devine S.M., Vij R., Rettig M. et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/ SDF-1 interaction. Blood 2008;112: 990–8.Devine S.M., Vij R., Rettig M. et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/ SDF-1 interaction. Blood 2008;112: 990–8.10. Fruehauf S., Veldwijk M.R., Seeger T. et al. A combination of granulocyte-colonystimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009;11:992–1001.Fruehauf S., Veldwijk M.R., Seeger T. et al. A combination of granulocyte-colonystimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009;11:992–1001.11. Fruehauf S. Current clinical indication for plerixafor. Transfus Med Hemother 2013;40:246–50.Fruehauf S. Current clinical indication for plerixafor. Transfus Med Hemother 2013;40:246–50.12. McCullough J., Clay M., Herr G. et al. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999;39(10):1136–40.McCullough J., Clay M., Herr G. et al. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999;39(10):1136–40.